Enkel de commercial highlights. De rest te vinden in press release
ommercial highlights
? Commercial cartridge volume – During Q3 2020, overall commercial cartridge volumes recovered from the
significant impact of the pandemic in Q2 2020 and grew 61% year-on-year. With year-to-date growth in
commercial cartridge volume in Q3 2020 standing at 27%, Biocartis is on track to achieve the targeted 30%
growth for FY2020. The US returned to the growth of commercial cartridge volumes in oncology, complemented
by initial sales of the Idylla™ SARS-CoV-2 Test1
. European markets showed consistent growth within oncology,
fully in line with pre-pandemic expectations. In Rest of World (RoW4
) markets, the year-on-year growth during
Q3 2020 was moderate, while year-to-date growth is still stalling due to the continued impact of the pandemic.
? Installed base – During Q3 2020, the Idylla™ installed base continued to expand, with the US representing 50%
of all new Idylla™ placements. The lingering impact of the pandemic continued to slow down the Idylla™
instrument growth in RoW markets.
? Regulatory update RoW markets – End of October 2020, the Taiwan FDA (TFDA) has accepted registrations for
the Idylla™ platform and the Idylla™ EGFR Mutation Test (CE-IVD).